Protara Therapeutics (TARA) Stock Price, News & Analysis

Company Overview

Protara Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy, which is in Phase II clinical trial for the treatment of non-muscle invasive bladder cancer and lymphatic malformations. It is also developing intravenous choline chloride, an investigational phospholipid substrate replacement therapy that is in Phase II clinical trial for patients receiving parenteral nutrition. The company is headquartered in New York, New York.

Key Stats

• Today's Range: $3.10 to $3.21
• 50-Day Range: $2.78 to $3.42
• 52-Week Range: $1.60 to $10.48
• Volume: 265,827 shs
• Average Volume: 196,708 shs
• Market Capitalization: $120.76 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $20.50
• Consensus Rating: Buy

Protara Therapeutics Stock Analysis - MarketRank™

Protara Therapeutics scored higher than 28% of companies evaluated by MarketBeat, and ranked 758th out of 923 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.6 / 5
• Analyst Rating: Buy

Consensus Rating

Protara Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.14, and is based on 6 buy ratings, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

Protara Therapeutics has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Protara Therapeutics are expected to decrease in the coming year, from ($3.32) to ($3.40) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Protara Therapeutics is -1.82, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Protara Therapeutics is -1.82, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Protara Therapeutics has a P/B Ratio of 0.66. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

7.49% of the outstanding shares of Protara Therapeutics have been sold short.

Short Interest Ratio / Days to Cover

Protara Therapeutics has a short interest ratio ("days to cover") of 7.1.

Change versus previous month

Short interest in Protara Therapeutics has recently increased by 2.12%, indicating that investor sentiment is decreasing.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Protara Therapeutics does not currently pay a dividend.

Dividend Growth

Protara Therapeutics does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

7.49% of the outstanding shares of Protara Therapeutics have been sold short.

Short Interest Ratio / Days to Cover

Protara Therapeutics has a short interest ratio ("days to cover") of 7.1.

Change versus previous month

Short interest in Protara Therapeutics has recently increased by 2.12%, indicating that investor sentiment is decreasing.

News and Social Media

• Score: 1.1 / 5
• News Sentiment: N/A

Search Interest

7 people have searched for TARA on MarketBeat in the last 30 days. This is an increase of 40% compared to the previous 30 days.

MarketBeat Follows

8 people have added Protara Therapeutics to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 0.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Protara Therapeutics insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 8.40% of the stock of Protara Therapeutics is held by insiders.

Percentage Held by Institutions

Only 38.13% of the stock of Protara Therapeutics is held by institutions.

TARA Stock Analysis - Frequently Asked Questions

How have TARA shares performed this year?

Protara Therapeutics' stock was trading at $5.28 on January 1st, 2025. Since then, TARA stock has decreased by 40.7% and is now trading at $3.13.

How were Protara Therapeutics' earnings last quarter?

Protara Therapeutics, Inc. (NASDAQ:TARA) posted its quarterly earnings results on Thursday, May, 8th. The company reported ($0.29) earnings per share for the quarter, topping the consensus estimate of ($0.47) by $0.18.

Who are Protara Therapeutics' major shareholders?

Protara Therapeutics' top institutional shareholders include Geode Capital Management LLC (1.93%), Intech Investment Management LLC (0.04%), Los Angeles Capital Management LLC (0.04%) and Police & Firemen s Retirement System of New Jersey (0.03%). Insiders that own company stock include Jesse Shefferman, Jacqueline Zummo and Opaleye Management Inc.
View institutional ownership trends.

How do I buy shares of Protara Therapeutics?

Shares of TARA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Protara Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Protara Therapeutics investors own include Digital Turbine (APPS), SoFi Technologies (SOFI), Canoo (GOEV), ChargePoint (CHPT) and CrowdStrike (CRWD).

Company Calendar

• Last Earnings: 5/08/2025
• Today: 8/09/2025
• Next Earnings (Estimated): 8/12/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - DRUGS
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:TARA
• CIK: 1359931
• Web: www.proteontherapeutics.com
• Phone: (646) 844-0337
• Fax: 781-487-6729
• Employees: 30
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Protara Therapeutics: $20.50
• High Price Target: $25.00
• Low Price Target: $12.00
• Potential Upside/Downside: +555.0%
• Consensus Rating: Buy
• Rating Score (0-4): 3.14
• Research Coverage: 7 Analysts

Profitability

• EPS (Trailing Twelve Months): ($1.72)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$44.60 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -36.37%
• Return on Assets: -33.29%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 18.03
• Quick Ratio: 18.03

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $4.77 per share
• Price / Book: 0.66

Miscellaneous

• Outstanding Shares: 38,580,000
• Free Float: 35,341,000
• Market Cap: $120.76 million
• Optionable: Optionable
• Beta: 1.42